Hasil Pencarian  ::  Simpan CSV :: Kembali

"Sustained release tablet is solid oral dosage form which is designed to release drugs slowly in the body. This research was conducted to make and characterize the cross-linked excipient of coprocessed polyvinyl alcohol-amylose as matrix for sustained release tablet with diclofenac sodium as the model drug. Cross-linked excipient of coprocessed polyvinyl alcohol-amylose (CL6 Co-PVA-A) was resulted from coprocessed excipient of polyvinyl alcohol-amylose (Co-PVA-A) that have been crosslinked with sodium trimetaphosphate. Meanwhile, Co-PVA-A was originated from two excipients, which are polyvinyl alcohol and amylose that have been coprocessed with ratio 1:2, 1:1, and 2:1. Co-PVA-A and CL6 Co-PVA-A properties were characterized physically, chemically, and functionally. Co-PVA-A and CL6 Co-PVA-A were formulated with dry granulation method in sustained release tablet as matrix. Furthermore, the sustained release tablets were evaluated and the drug release profiles were studied. As results, substitution degree of CL6 Co-PVA-A 1:2, 1:1, and 2:1 are respectively 0.080; 0.069; and 0.086. Those excipients have good swelling capability and gel strength that are 5.02; 5.22; and 5.12 gf. All sustained release tablet passed the requirement of weight variation, hardness, friability, and assay. CL6 Co-PVA-A as matrices (F1, F2, and F3) showed first order (F1) and zero order (F2 and F3) drug release kinetics. This study suggested that the tablets can be applied as sustained release tablets and retard drug release up to 16 hours.

---

Sustained release tablet is solid oral dosage form which is designed to release drugs slowly in the body. This research was conducted to make and characterize the cross-linked excipient of coprocessed polyvinyl alcohol-amylose as matrix for sustained release tablet with diclofenac sodium as the model drug. Cross-linked excipient of coprocessed polyvinyl alcohol-amylose (CL6 Co-PVA-A) was resulted from coprocessed excipient of polyvinyl alcohol-amylose (Co-PVA-A) that have been crosslinked with sodium trimetaphosphate. Meanwhile, Co-PVA-A was originated from two excipients, which are polyvinyl alcohol and amylose that have been coprocessed with ratio 1:2, 1:1, and 2:1. Co-PVA-A and CL6 Co-PVA-A properties were characterized physically, chemically, and functionally. Co-PVA-A and CL6 Co-PVA-A were formulated with dry granulation method in sustained release tablet as matrix. Furthermore, the sustained release tablets were evaluated and the drug release profiles were studied. As results, substitution degree of CL6 Co-PVA-A 1:2, 1:1, and 2:1 are respectively 0.080; 0.069; and 0.086. Those excipients have good swelling capability and gel strength that are 5.02; 5.22; and 5.12 gf. All sustained release tablet passed the requirement of weight variation, hardness, friability, and assay. CL6 Co-PVA-A as matrices (F1, F2, and F3) showed first order (F1) and zero order (F2 and F3) drug release kinetics. This study suggested that the tablets can be applied as sustained release tablets and retard drug release up to 16 hours."

"Praktek Kerja Profesi Apoteker dilaksanakan di PT. Novell Pharmaceutical Laboratories Jalan Pos Pengumben Raya No.8, Jakarta Barat. Kegiatan PKPA ini bertujuan agar mahasiswa profesi apoteker dapat melihat langsung aktivitas yang berlangsung dalam suatu industri farmasi, memperoleh pengetahuan dan wawasan tentang segala aspek yang terkait di industri farmasi terutama dalam hal registrasi produk di PT. Novell Pharmaceutical Laboratories dan dapat memiliki pemahaman yang mendalam mengenai peran dan tugas apoteker di industri farmasi. Tugas khusus yang diberikan berjudul Tata Laksana Pendaftaran Suplemen Makanan. Tugas khusus ini bertujuan untuk memberikan pemahaman kepada mahasiswa mengenai pendaftaran suplemen makanan di BPOM sebelum mendapatkan izin edar.

---

Pharmacists Professional Practice implemented in PT. Novell Pharmaceutical Laboratories Pos Pengumben Jalan Raya No. 8, West Jakarta. PKPA activity is intended that the student pharmacist profession can see the activity that takes place directly in the pharmaceutical industry, gaining knowledge and insight into everything related aspects in the pharmaceutical industry, especially in terms of product registration in PT. Novell Pharmaceutical Laboratories and can have a deep understanding of the roles and duties of pharmacists in the pharmaceutical industry. Given a special task called Food Supplements Registration Procedure. This particular task aims to provide insight to students regarding registration of food supplements in BPOM before obtaining marketing authorization."

"Praktek Kerja Profesi Apoteker di Suku Dinas Kesehatan Kota Administrasi Jakarta Barat bertujuan untuk memahami tugas dan fungsi Suku Dinas Kesehatan Kota Jakarta Barat dan juga memahami tugas pokok dan fungsi dari bagian tenaga kesehatan bagian standarisasi mutu kesehatan dan bagian farmasi makanan dan minuman yang termasuk di dalam seksi sumber daya kesehatan SDK Sedangkan tujuan dari tugas khusus adalah untuk mengetahui kesesuaian jumlah pemakaian obat dalam resep dengan pengeluaran fisik obat di Puskesmas Kecamatan Kembagan.

---

Pharmacists Professional Practice in Suku Dinas Kesehatan Kota Administrasi Jakarta Barat aims to understand the duties and functions of parts of West Jakarta Health Office and also to understand the duties and functions of the part of health personnel parts standardization and quality health pharmacy food and beverage included in the resources in the health section SDK While the purpose of the special task is to determine the appropriateness of the amount of drug in the prescription drug expenditure in physical Puskesmas Kembagan."

"Epidermal Growth Factor (EGF) merupakan polipeptida yang mendorong terjadinya proses pertumbuhan, proliferasi, dan diferensiasi sel, juga digunakan sebagai kosmetik anti-aging. Akan tetapi, EGF memiliki ukuran molekul yang besar sehingga dapat menyulitkan penetrasinya ke kulit. Penelitian ini bertujuan untuk membuat dan mengkarakterisasi transfersom rhEGF dalam sediaan emulgel dan mempelajari profil penetrasinya ke kulit. Pada penelitian ini dilakukan optimasi formula transfersom dengan perbandingan antara fosfolipid dan surfaktan yang berbeda. Hasil menunjukkan bahwa formula TF3 dengan perbandingan 80:20 merupakan formula dengan karakteristik terbaik, sehingga formula ini digunakan untuk mengenkapsulasi rhEGF. Transfersom rhEGF dibuat sebanyak tiga formula, dengan konsentrasi rhEGF yang berbeda-beda. Karakteristik terbaik dimiliki oleh formula TF-EGF1 dengan konsentrasi rhEGF 0,025%, yaitu bentuk vesikel sferis, Zaverage 128,1 ± 0,66 nm, indeks deformabilitas 1,254 ± 0,02, indeks polidispersitas 0,109 ± 0,004, potensial zeta -43,1 ± 1,07 mV, dan efisiensi penjerapan 97,77 ± 0,06%. Ketiga formula diformulasikan ke dalam sediaan emulgel (ETF1 - ETF3) dan diuji penetrasi in vitro dengan emulgel rhEGF non-transfersom (ENTF) sebagai pembanding. Hasil menunjukkan bahwa formula ETF1 menunjukkan peningkatan fluks terbesar, yaitu 5,56 kali dibandingkan formula ENTF. Oleh karena itu, emulgel transfersom rhEGF memiliki potensi untuk digunakan sebagai kosmetik anti-aging.

---

Epidermal Growth Factor (EGF) is a polypeptide that promotes the process of growth, proliferation, and cell differentiation, also used as an anti-aging cosmetics. However, EGF has a large molecular size that can make it difficult to penetrate the skin. This study aims to create and characterize rhEGF transfersom in emulgel preparations and study its penetration profile into the skin. In this study, optimization of transferom formulation was carried out with several ratios between phospholipid and surfactants. The results show that the TF3 formula with a ratio of 80:20 was the formula with the best characteristics, so it was used to encapsulate rhEGF. rhEGF transfersomes were made in three formulas, with different rhEGF concentrations. The best characteristics were obtained by the formula TF-EGF1 with 0.025% rhEGF concentration, which had spherical vesicle, Zaverage of 128.1 ± 0.66 nm, deformability index of 1.254 ± 0.02, polydispersity index of 0.109 ± 0.004, zeta potential of  -43.1 ± 1.07 mV, and encapsulation efficiency of 97.77 ± 0.06%. The three formulas were formulated into emulgel preparations (ETF1 - ETF3) and tested in vitro with non-transferom rhEGF emulgel (ENTF) as a comparison. The results showed that the ETF1 formula showed the largest increase in flux, which was 5.56 times compared to the ENTF formula. Therefore, rhEGF transfersomal emulgel has the potential to be used as an anti-aging cosmetic."